A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
- Type
- Retraction
- Notice date
- 7/7/2023 0:00
- Journal
- BMC Cancer
- Publisher
- Springer - Biomed Central (BMC)
- Notice DOI
- 10.1186/s12885-023-11135-3
- Original paper DOI
- 10.1186/1471-2407-13-527
Reasons
- Author Unresponsive
- Duplication of/in Image
- Duplication of Text
- Euphemisms for Duplication
- Objections by Author(s)